eflapegrastim
Spectrum Pharms
To decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia
The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.
git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/
Example prompts for Rolvedon: